Synergistic induction of erlotinib-mediated apoptosis by resveratrol in human non-small-cell lung cancer cells by down-regulating survivin and up-regulating PUMA

Cellular Physiology and Biochemistry

Volumn 35, Issue 6, 2015, Pages 2255-2271

  Nie, Peipei ^a,d   Hu, Weicheng ^b   Zhang, Tao ^a   Yang, Yiju ^c   Hou, Benxin ^c   Zou, Zhengzhi ^a  

^a SOUTH CHINA NORMAL UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c Hainan Province Nongken Sanya Hospital   (China)

^d GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Erlotinib; NSCLC; PUMA; Resveratrol; Survivin; Synergistic

Indexed keywords

CASPASE 3; CASPASE 8; ERLOTINIB; FLUORESCEIN ISOTHIOCYANATE; LIPOCORTIN 5; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN KINASE B; PROTEIN MCL 1; PROTEIN P53; PUMA PROTEIN; REACTIVE OXYGEN METABOLITE; RESVERATROL; SMALL INTERFERING RNA; SURVIVIN; APOPTOSIS REGULATORY PROTEIN; BBC3 PROTEIN, HUMAN; BIRC5 PROTEIN, HUMAN; INHIBITOR OF APOPTOSIS PROTEIN; MCL1 PROTEIN, HUMAN; ONCOPROTEIN; S6 KINASE; STILBENE DERIVATIVE; TARGET OF RAPAMYCIN KINASE;

A549 CELL LINE; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL VIABILITY; CLONOGENESIS; COLONY FORMATION; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; ENZYME ACTIVITY; ENZYME INHIBITION; FLOW CYTOMETRY; GENE EXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; LUNG CANCER CELL LINE; MTT ASSAY; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING; CARCINOMA, NON-SMALL-CELL LUNG; DRUG EFFECTS; DRUG POTENTIATION; LUNG NEOPLASMS; METABOLISM; TUMOR CELL LINE;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CARCINOMA, NON-SMALL-CELL LUNG; CASPASE 3; CELL LINE, TUMOR; DOWN-REGULATION; DRUG SYNERGISM; ERLOTINIB HYDROCHLORIDE; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; LUNG NEOPLASMS; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; REACTIVE OXYGEN SPECIES; RIBOSOMAL PROTEIN S6 KINASES; SIGNAL TRANSDUCTION; STILBENES; TOR SERINE-THREONINE KINASES; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 84928151834     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000374030     Document Type: Article

References (36)

1. Saintigny P, Burger JA: Recent advances in non-small cell lung cancer biology and clinical management. Discov Med 2012;13:287-297.
2. Johnson DH, Schiller JH, Bunn PJ: Recent clinical advances in lung cancer management. J Clin Oncol 2014;32:973-982.
3. Yun M, Kim EO, Lee D, Kim JH, Kim J, Lee H, Lee J, Kim SH: Melatonin sensitizes H1975 non-small-cell lung cancer cells harboring a T790M-targeted epidermal growth factor receptor mutation to the tyrosine kinase inhibitor gefitinib. Cell Physiol Biochem 2014;34:865-872.
4. Nicholson RI, Gee JM, Harper ME: EGFR and cancer prognosis. Eur J Cancer 2001;37:S9-S15.
5. Baselga J, Albanell J: Targeting epidermal growth factor receptor in lung cancer. Curr Oncol Rep 2002;4:317-324.
6. Bonomi P: Erlotinib: A new therapeutic approach for non-small cell lung cancer. Expert Opin Investig Drugs 2003;12:1395-1401.
7. Hightower M: Erlotinib (OSI-774, Tarceva), a selective epidermal growth factor receptor tyrosine kinase inhibitor, in combination with chemotherapy for advanced non-small-cell lung cancer. Clin Lung Cancer 2003;4:336-338.
8. Yu S, Zhang B, Xiang C, Shu Y, Wu H, Huang X, Yu Q, Yin Y, Guo R: Prospective assessment of pemetrexed or pemetrexed plus platinum in combination with gefitinib or erlotinib in patients with acquired resistance to gefitinib or erlotinib: A phase II exploratory and preliminary study. Clin Lung Cancer 2015;16:121-127.
9. Lin Y, Wang X, Jin H: EGFR-TKI resistance in NSCLC patients: Mechanisms and strategies. Am J Cancer Res 2014;4:411-435.
10. Oxnard GR, Arcila ME, Chmielecki J, Ladanyi M, Miller VA, Pao W: New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer. Clin Cancer Res 2011;17:5530-5537.
11. Santandreu FM, Valle A, Oliver J, Roca P: Resveratrol potentiates the cytotoxic oxidative stress induced by chemotherapy in human colon cancer cells. Cell Physiol Biochem 2011;28:219-228.
12. Borriello A, Bencivenga D, Caldarelli I, Tramontano A, Borgia A, Zappia V, Della RF: Resveratrol: From basic studies to bedside. Cancer Treat Res 2014;159:167-184.
13. Wu Y, Liu F: Targeting mTOR: Evaluating the therapeutic potential of resveratrol for cancer treatment. Anticancer Agents Med Chem 2013;13:1032-1038.
14. Chan CM, Chang HH, Wang VC, Huang CL, Hung CF: Inhibitory effects of resveratrol on PDGF-BB-induced retinal pigment epithelial cell migration via PDGFRbeta, PI3K/Akt and MAPK pathways. PLoS One 2013;8:e56819.
15. Luo H, Yang A, Schulte BA, Wargovich MJ, Wang GY: Resveratrol induces premature senescence in lung cancer cells via ROS-mediated DNA damage. PLoS One 2013;8:e60065.
16. Patel KR, Brown VA, Jones DJ, Britton RG, Hemingway D, Miller AS, West KP, Booth TD, Perloff M, Crowell JA, Brenner DE, Steward WP, Gescher AJ, Brown K: Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients. Cancer Res 2010;70:7392-7399.
17. Scott E, Steward WP, Gescher AJ, Brown K: Resveratrol in human cancer chemoprevention-choosing the 'right' dose. Mol Nutr Food Res 2012;56:7-13.
18. Chou TC, Talalay P: Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
19. Zou Z, Yuan Z, Zhang Q, Long Z, Chen J, Tang Z, Zhu Y, Chen S, Xu J, Yan M, Wang J, Liu Q: Aurora kinase a inhibition-induced autophagy triggers drug resistance in breast cancer cells. Autophagy 2012;8:1798-1810.
20. Schieber M, Chandel NS: ROS function in redox signaling and oxidative stress. Curr Biol 2014;24:R453-R462.
21. Bassing CH, Suh H, Ferguson DO, Chua KF, Manis J, Eckersdorff M, Gleason M, Bronson R, Lee C, Alt FW: Histone H2AX: A dosage-dependent suppressor of oncogenic translocations and tumors. Cell 2003;114:359-370.
22. Roy SK, Chen Q, Fu J, Shankar S, Srivastava RK: Resveratrol inhibits growth of orthotopic pancreatic tumors through activation of FOXO transcription factors. PLoS One 2011;6:e25166.
23. Lou YF, Zou ZZ, Chen PJ, Huang GB, Li B, Zheng DQ, Yu XR, Luo XY: Combination of gefitinib and DNA methylation inhibitor decitabine exerts synergistic anti-cancer activity in colon cancer cells. PLoS One 2014;9:e97719.
24. Masuelli L, Di Stefano E, Fantini M, Mattera R, Benvenuto M, Marzocchella L, Sacchetti P, Focaccetti C, Bernardini R, Tresoldi I, Izzi V, Mattei M, Frajese GV, Lista F, Modesti A, Bei R: Resveratrol potentiates the in vitro and in vivo anti-tumoral effects of curcumin in head and neck carcinomas. Oncotarget 2014;5:10745-10762.
25. Alayev A, Berger SM, Kramer MY, Schwartz NS, Holz MK: The combination of rapamycin and resveratrol blocks autophagy and induces apoptosis in breast cancer cells. J Cell Biochem 2015;116:450-457.
26. Yang Q, Wang B, Zang W, Wang X, Liu Z, Li W, Jia J: Resveratrol inhibits the growth of gastric cancer by inducing G1 phase arrest and senescence in a Sirt1-dependent manner. PLoS One 2013;8:e70627.
27. Hu Y, Rahlfs S, Mersch-Sundermann V, Becker K: Resveratrol modulates mRNA transcripts of genes related to redox metabolism and cell proliferation in non-small-cell lung carcinoma cells. Biol Chem 2007;388:207-219.
28. Lainey E, Sebert M, Thepot S, Scoazec M, Bouteloup C, Leroy C, De Botton S, Galluzzi L, Fenaux P, Kroemer G: Erlotinib antagonizes ABC transporters in acute myeloid leukemia. Cell Cycle 2012;11:4079-4092.
29. Kim Y, Kim YS, Kim DE, Lee JS, Song JH, Kim HG, Cho DH, Jeong SY, Jin DH, Jang SJ, Seol HS, Suh YA, Lee SJ, Kim CS, Koh JY, Hwang JJ: BIX-01294 induces autophagy-associated cell death via EHMT2/G9a dysfunction and intracellular reactive oxygen species production. Autophagy 2013;9:2126-2139.
30. Scott TL, Rangaswamy S, Wicker CA, Izumi T: Repair of oxidative DNA damage and cancer: Recent progress in DNA base excision repair. Antioxid Redox Signal 2014;20:708-726.
31. Degterev A, Huang Z, Boyce M, Li Y, Jagtap P, Mizushima N, Cuny GD, Mitchison TJ, Moskowitz MA, Yuan J: Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat Chem Biol 2005;1:112-119.
32. Laplante M, Sabatini DM: MTOR signaling at a glance. J Cell Sci 2009;122:3589-3594.
33. Wendel HG, De Stanchina E, Fridman JS, Malina A, Ray S, Kogan S, Cordon-Cardo C, Pelletier J, Lowe SW: Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 2004;428:332-337.
34. Altieri DC: Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer 2008;8:61-70.
35. McMurtry MS, Archer SL, Altieri DC, Bonnet S, Haromy A, Harry G, Bonnet S, Puttagunta L, Michelakis ED: Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension. J Clin Invest 2005;115:1479-1491.
36. Ye Q, Cai W, Zheng Y, Evers BM, She QB: ERK and AKT signaling cooperate to translationally regulate survivin expression for metastatic progression of colorectal cancer. Oncogene 2014;33:1828-1839.